ChemoCentryx, Inc.
DelistedCIK 1340652fmd_06R0EX98SMRR98019RZ6AJXTXGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2022, 47 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 12 | 82 | 43 | 36 | 65 | 32 |
| Research and development | 35 | 34 | 34 | 33 | 38 | 49 | 63 | 70 | 78 | 83 |
| Selling, general and administrative | – | – | – | – | – | – | – | 24 | 42 | 79 |
| Operating income | (40) | (39) | (47) | (48) | (41) | 16 | (40) | (58) | (55) | (130) |
| Interest expense | 1 | 0 | 0 | – | – | 0 | 1 | 2 | 3 | 3 |
| Interest and investment income | 1 | 1 | 0 | 0 | 1 | 1 | 4 | 5 | 2 | 1 |
| Other non-operating income (expense) | (0) | 0 | 0 | 0 | 1 | 1 | 2 | 3 | (0) | (2) |
| Income before taxes | (40) | – | – | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (40) | (39) | (47) | (47) | (40) | 18 | (38) | (55) | (55) | (132) |